Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426899 | 0.91 | GCK (0.63) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL1426959 | 0.90 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL12579748 | 0.90 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL13268823 | 0.90 | GCK (0.60) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL13268632 | 0.89 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL13268633 | 0.89 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL13557909 | 0.89 | GCK (0.61) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL2667075 | 0.89 | GCK (0.59) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL12579106 | 0.88 | GCK (0.64) | GCKCYP1A2ABCB1CYP3A4CYP2C8 | |
| SCHEMBL12579843 | 0.87 | GCK (0.58) | GCKCYP1A2ABCB1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277208-A1 | BENZAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277208-A1 | BENZAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2511265-A1 | BENZAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511265-A1 | BENZAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071095-A1 | BENZAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277208-A1 | BENZAMIDE COMPOUND | GK, GCKR, GPR119 | GCK 14/4885CYP1A2 1587/4885ABCB1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.